Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bruton’s Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis
Neeta Garg, Elizabeth Jordan Padron, Kottil Rammohan, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 20, pp. 6139-6139
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials
Dariusz Rozkiewicz, Justyna Magdalena Hermanowicz, Iwona Kwiatkowska, et al.
Molecules (2023) Vol. 28, Iss. 5, pp. 2400-2400
Open Access | Times Cited: 42
Inborn errors of human B cell development, differentiation, and function
Stuart G. Tangye, Tina Nguyen, Elissa K. Deenick, et al.
The Journal of Experimental Medicine (2023) Vol. 220, Iss. 7
Open Access | Times Cited: 26
PROTACs: A novel strategy for cancer drug discovery and development
Xin Han, Yi Sun
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 25
Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis
Douglas L. Arnold, Colm Elliott, Emily C. Martin, et al.
Neurology (2024) Vol. 102, Iss. 5
Open Access | Times Cited: 11
Current Treatment Approach, Emerging Therapies and New Horizons in Systemic Lupus Erythematosus
Panagiotis Athanassiou, Lambros Athanassiou
Life (2023) Vol. 13, Iss. 7, pp. 1496-1496
Open Access | Times Cited: 15
Towards a biological view of multiple sclerosis from early subtle to clinical progression: an expert opinion
Massimo Filippi, Maria Pia Amato, Carlo Avolio, et al.
Journal of Neurology (2025) Vol. 272, Iss. 2
Open Access
Design, synthesis, and biological evaluation of novel azaspirooxindolinone derivatives as potent inhibitors of ITK and BTK-dependent cancers
Gopal Mudasani, Naveen Kumar Rampeesa, Sreenivasa Anugu, et al.
Bioorganic & Medicinal Chemistry (2025) Vol. 121, pp. 118116-118116
Closed Access
Protective effects of BTK inhibition by acalabrutinib on cisplatin-induced renal and testicular injury in mice: Modulation of mTOR/AMPK, NLRP3/GSDMD-N, and apoptotic pathways.
Sara H. Hazem, Karim M. Saad, Mahmoud M. Samaha
International Immunopharmacology (2025) Vol. 149, pp. 114256-114256
Closed Access
Recent highlights in covalent inhibitor design
Kristen A. Marino, Robert Nicewonger, Hailong Zhang, et al.
Elsevier eBooks (2025)
Closed Access
Inflammatory Demyelinating Diseases of the Central Nervous System
Minshu Li, Qiang Liu
Advances in neurobiology (2024), pp. 171-218
Closed Access | Times Cited: 3
Bruton’s tyrosine kinase as a promising therapeutic target for multiple sclerosis
Darius Saberi, Anastasia Geladaris, Sarah Dybowski, et al.
Expert Opinion on Therapeutic Targets (2023) Vol. 27, Iss. 4-5, pp. 347-359
Open Access | Times Cited: 8
The Evolving Role of Bruton’s Tyrosine Kinase Inhibitors in B Cell Lymphomas
Shefali Mehra, M. Gary Nicholls, Justin Taylor
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 14, pp. 7516-7516
Open Access | Times Cited: 2
Oral Chronic Graft-Versus-Host Disease: Pathogenesis, Diagnosis, Current Treatment, and Emerging Therapies
Joe Nguyen, Maryam Jessri, Ana Caroline Costa-da-Silva, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 19, pp. 10411-10411
Open Access | Times Cited: 2
Recent research of BTK inhibitors: Methods of structural design, pharmacological activities, manmade derivatives and structure–activity relationship
Lin Wang, Zhengjie Zhang, Dongke Yu, et al.
Bioorganic Chemistry (2023) Vol. 138, pp. 106577-106577
Closed Access | Times Cited: 6
Evaluation of Bruton tyrosine kinase inhibitors monotherapy and combination therapy in lymphocytic leukemia
Xiangxing Liu, Binyi Hu, Nan Peng, et al.
Clinical and Experimental Medicine (2023) Vol. 23, Iss. 8, pp. 4237-4248
Closed Access | Times Cited: 4
Unleashing the Potential of Ibrutinib-Loaded Nanoparticles for Cancer Treatment—A Comprehensive Review
Razieh Behzadmehr, Sonia Fathi‐karkan, Sobia Razzaq, et al.
BioNanoScience (2024) Vol. 14, Iss. 3, pp. 3784-3797
Closed Access | Times Cited: 1
A Comprehensive Review of Small-Molecule Inhibitors Targeting Bruton Tyrosine Kinase: Synthetic Approaches and Clinical Applications
Qi Zhang, Changming Wen, Zhao Li-jie, et al.
Molecules (2023) Vol. 28, Iss. 24, pp. 8037-8037
Open Access | Times Cited: 3
Investigation of Fenebrutinib Metabolism and Bioactivation Using MS3 Methodology in Ion Trap LC/MS
Aishah M. Alsibaee, Haya I. Aljohar, Mohamed W. Attwa, et al.
Molecules (2023) Vol. 28, Iss. 10, pp. 4225-4225
Open Access | Times Cited: 2
Bruton’s Tyrosine Kinase Inhibitors for Multiple Sclerosis Treatment
Benjamin Greenberg
Neurologic Clinics (2023) Vol. 42, Iss. 1, pp. 155-163
Closed Access | Times Cited: 2
Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton’s tyrosine kinase inhibitor
Amit Bar‐Or, Anne H. Cross, Anthony L. Cunningham, et al.
Multiple Sclerosis Journal (2023) Vol. 29, Iss. 11-12, pp. 1471-1481
Open Access | Times Cited: 2
Advancements in B‐Cell Non‐Hodgkin’s Lymphoma: From Signaling Pathways to Targeted Therapies
Abdullah Alfaifi, Salem Bahashwan, Mohammed Alsaadi, et al.
Advances in Hematology (2024) Vol. 2024, Iss. 1
Open Access
Human Immunodeficiencies Caused by Inborn Errors of B-Cell Development or Function
Stuart G. Tangye, Jean‐Laurent Casanova, S. Cindy
Elsevier eBooks (2024), pp. 335-365
Closed Access
Multiple Sclerosis: Immune Cells, Histopathology, and Therapeutics
Manisha S. Patil, Linda Yingqi Lin, Felix Marsh‐Wakefield, et al.
Sclerosis (2024) Vol. 2, Iss. 3, pp. 117-139
Open Access
Cardio-oncology Drug Interactions
Craig J. Beavers, Alana Ferrari
Cardiology Clinics (2024) Vol. 43, Iss. 1, pp. 169-194
Closed Access
Role of Bruton's Tyrosine Kinase (BTK) in the Treatment of Cognitive Impairment in Patients with Multiple Sclerosis
Elnaz Asadollahzadeh, Zahra Ebadi, Nasim Rezaeimanesh, et al.
(2023)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top